French analysts' fury over government fee decision:
This article was originally published in Clinica
The outgoing French government has rejected an agreement drawn up between three associations representing clinical analysts and the national healthcare insurer, CNAM, in a move that has provoked anger and frustration. The government is opposed to the fees increase in clinical analyses from E0.26 ($0.24) to E0.27 claiming that it would cost an additional E87.75 million to the national sickness insurance funds, an increase of 4.7% on current spending levels. The associations representing clinical analysts are furious, demanding to know what use agreements are if the government can simply overturn them. They hope, however, that the next government will be open to further discussion.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.